Ronald Labrum, Chairman
Ron Labrum is an experienced operator and leader in healthcare distribution and medical device sectors. He began his career with American Hospital Supply and spent over 25 years with Baxter International, Allegiance Healthcare, and Cardinal Health. Most recently he was CEO of Fenwal, Inc., a private equity-backed spinout of Baxter’s device business focused on blood technologies. Ron’s career has been distinguished by leadership roles in sales, operations, and manufacturing, as well as the execution and integration of several mergers and acquisitions. Ron currently serves on the Boards of Directors of Ortho-Clinical Diagnostics, Wright Medical, Aptalis, and Suture Express.
Shervin is the President and CEO of BVI. He brings to BVI general management, operational, financial, and investment experience across a diverse array of industries including healthcare, consumer products, industrial manufacturing and financial services. His experiences also span internationally including the US, Switzerland, France, Ireland and the United Kingdom. Prior to BVI, Shervin was a senior executive with Swiss-headquartered Novartis Group AG. Before Novartis, he started his career and spent 15 years with The Blackstone Group, one of the world’s leading alternative investment firms, most recently as a Managing Director. In addition to the Board of BVI, he currently serves on the Board of Directors of Hain Celestial (Nasdaq: HAIN) and Motus GI (Nasdaq: MOTS). In addition, Shervin serves on the Wharton Leadership Advisory Board, established by the Center for Leadership and Change Management at the University of Pennsylvania.
Mark S. Blumenkranz, MD, MMS
Mark Blumenkranz is the HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University, Managing Director of Lagunita Biosciences, and Chairman and CEO of Kedalion Therapeutics. He is an internationally known vitreo-retinal specialist, with notable contributions in the area of new laser systems, novel pharmaceuticals for macular diseases, ocular gene therapy, and ophthalmic tele-health and technology development. He was a Director at Oculex Pharmaceuticals prior to its acquisition by Allergan. He was a founder and Director of Peak Surgical, acquired by Medtronics, and Optimedica, which was acquired by AMO and is now part of Johnson and Johnson. Mark co-founded and served as the first Chairman of the Board of Adverum Biotechnologies and was a co-founder and Director of Oculeve, also acquired by Allergan. He is a co-founder and serves as a Director of Verana Health and is a member of the Boards of Directors of One Medical, Kala Therapeutics (NASDAQ:KALA) and Iveric Bio.
Kendall Garrison is a Partner at TPG Capital based in San Francisco, where he focuses on investments in the healthcare sector. Kendall serves on the boards of BVI Medical, Confluent Medical Technologies, Exactech, Kelsey-Seybold Clinic and Monogram Health (Observer). He previously served on the boards of Kindred at Home and Kindred Healthcare and has also been involved in TPG’s investments in Immucor and Surgical Care Affiliates. Prior to joining TPG in 2008, Kendall worked at Goldman, Sachs & Co. in its investment banking division. Kendall received a BBA with Honors from the University of Wisconsin-Madison and an MBA from Harvard Business School.
Cindy Lucchese is Chief Strategy Officer of Penske Entertainment, a motorsports competition and entertainment company. She has served as the Senior Vice President and Chief Financial Officer of Hillenbrand, Inc., a public company with multiple brands that serve a range of industries across the globe, and has extensive experience with medical device and life sciences companies, including Guidant, Thoratec and Eli Lilly. Cindy serves on the Boards of Directors of Inari Medical, Intersect ENT, Inc., and Hanger, Inc.
Dana G. Mead, Jr.
Dana G. Mead, Jr., has more than 30 years of experience working with companies across the healthcare space, with a focus on identifying emerging medical technologies, developing new therapies, establishing new markets and building world-class management teams. Dana last served as President and CEO of Heartflow, Inc. He was previously the President and CEO of BVI and prior to that served as a Partner at Kleiner Perkins Caufield & Byers and as President of Guidant Vascular Intervention. He also held earlier sales and marketing roles with Allergan and Johnson & Johnson. Dana currently serves on the Boards of Directors of Inari Medical, Inspire Medical, Intersect ENT and Pulmonx.
Marc Nolet de Brauwere
Marc Nolet de Brauwere has over 20 years of experience in product development, business growth and operational leadership in the ophthalmic device industry, specifically in the area of intraocular lenses (IOLs) for cataract and refractive surgery. He acquired PhysIOL® in 1997 and led the organization through industry-leading growth and with consistent innovative product development designs and launches, including the world’s first trifocal IOL.
Jeff Rhodes is Co-Managing Partner of TPG Capital based in San Francisco. He also co-leads the healthcare group and the firm’s investment activities in the healthcare services, pharmaceutical, and medical device sectors. Jeff serves on the Boards of Directors of Immucor, Kelsey Seybold Clinic, LifeStance Health, Pediatric Associates, Troon and WellSky. He previously served on the Boards of Biomet, EnvisionRx, IMS Health, Kindred Healthcare, Kindred atHome, Par Pharmaceutical Companies, Surgical Care Affiliates, Zimmer Biomet and as a founding Board member of the Healthcare Private Equity Association. Jeff received his MBA from the Harvard Business School. He earned his BA in Economics from Williams College.
John Schilling is a Partner, leads the Operations team for TPG Capital, co-leads the Healthcare team for TPG Capital and is leading the launch of TPG’s Life Science Innovations franchise. John has served on the Board or played leadership roles in TPG’s investments in Adare Pharmaceuticals, Allogene, Aptalis, AskBio, BGB, BVI, Confluent, EnvisionRx, Exactech, Immucor, Kelsey Seybold, Kindred and Par Pharmaceutical. Prior to joining TPG in 2011, John managed Sales and Marketing for the U.S. pharmaceutical business at Abbott and was a Partner at McKinsey & Company. John received his undergraduate degree in Biomedical and Electrical Engineering from Duke, a Master’s in Biomedical Engineering from Johns Hopkins where he was a Bozzelli Scholar, and an M.D. from the University of Chicago where he received the Joseph A. Capps Award for the most outstanding student in clinical medicine. Thereafter, John conducted his residency training in surgery at Johns Hopkins.
Todd Smith previously served as President, CEO and Director of Assertio, President, CEO and Director of Zyla Life Sciences and Iroko Pharmaceuticals. He also held senior roles at Ophthotech Corporation and Horizon Therapeutics. With more than 25 years of pharmaceutical, medical device and biotechnology leadership, Todd has a long track record of building companies and achieving commercial and business development excellence while maintaining a focus on patient access to differentiated products. Todd currently serves as a Director for Vault Nano and Novos Growth Partners.